The state of Vitamin D in Iraqi Patients With Parkinson Disease

Aqeel Kareem. Hatem *, Hayder Fadhil Lateef**

ABSTRACT
Background: A role for vitamin D deficiency in Parkinson disease (PD) has recently been suggested.
Objective: To estimate the state of vitamin D in PD with an age-matched healthy control.
Type of the study: A case control study,
Method: The study randomly comparison of plasma 25-hydroxyvitamin D (25[OH] D) concentrations of collected samples in a clinical neurology department ward / Baghdad teaching hospital / Medical City and Parkinson disease movement disorder clinic. Participants were registered into the study from October 2015 to October 2016. We was study serum vitamin D level in 40 consecutive patients with Parkinson disease and 40 age-matched healthy controls after matching for age, sex, race, and geographic location.

Results: Significantly, more patients with PD (62.5%) had deficient vitamin D than did controls (27.5%). The mean 25(OH) D concentration in PD was (18.09) significantly lower than in the control (24.89).

Conclusions: This study demonstrates a significantly lower vitamin D level in PD than healthy controls. These data support a possible role of vitamin D deficiency in PD.

Keywords: Vitamin D, Iraq, Parkinson.

Objective: To estimate the state of vitamin D in Parkinson disease (PD) with an age-matched healthy control.

Method: This study randomly compared plasma 25-hydroxyvitamin D (25[OH] D) concentrations of collected samples in a clinical neurology department ward / Baghdad teaching hospital / Medical City and Parkinson disease movement disorder clinic. Participants were registered into the study from October 2015 to October 2016. We studied serum vitamin D level in 40 consecutive patients with Parkinson disease and 40 age-matched healthy controls after matching for age, sex, race, and geographic location.

Results: Significantly, more patients with PD (62.5%) had deficient vitamin D than did controls (27.5%). The mean 25(OH) D concentration in PD was (18.09) significantly lower than in the control (24.89).

Conclusions: This study demonstrates a significantly lower vitamin D level in PD than healthy controls. These data support a possible role of vitamin D deficiency in PD.

Keywords: Vitamin D, Iraq, Parkinson.

P arkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer disease, it an old term disorder of the central nervous system that mainly affects the motor system.1) The symptoms generally come on slowly over time. Early in the disease, the most obvious are shaking, rigidity, slowness of movement, and difficulty with walking.1) However, with current understanding of the disease, the main motor symptoms are collectively called "parkinsonism", or a "parkinsonian syndrome".2)

Table (1) [4]
differentiation, proliferation, and apoptosis. [16] In the brain, VDRs localize in the nucleus, whereas 1_\text{-} \text{OHase} is distributed throughout the cytosol. In particular, hippocampal and substantia nigra cells demonstrate high concentrations of VDRs and 1_\text{-} \text{OHase}. [15] Finally, the American geriatric society recommended vitamin D and calcium supplement to prevent fall in elderly. They recommended that 65 years old or older should consume 1000 I.U. vitamin D daily along with Calcium 1000-1200 mg daily. [17] One recent review of multiple study that vitamin D supplement in old people reduce fall by 20%. [18] Both biological plausibility and epidemiology data indicate that vitamin D level deficiency may contribute to the development of PD. [17]

**Aim of study:** To estimate the state of vitamin D in Parkinson patients.

**Methods:** Design and Setting: Case control study was conducted in the neurology wards / Baghdad teaching hospital/ medical city and movement disorder clinic. The selected patients attended the medical center from October 2015 until October 2016 during their periodic visit seeking for medical advice concerning their sign and symptoms of Parkinson disease.

**Study population:** This study performed on 40 patients (24 male and 16 female, with mean age 59.225, 23 urban and 17 rural) diagnosed with Parkinson disease according to bank criteria. Who attended neurology wards / Baghdad teaching hospital/ medical city and movement disorder clinic under supervision of consultant neurologist. Their selection follows the following criteria:

**Inclusion criteria:** Idiopathic Parkinson disease diagnosis by UK Parkinson's disease society brain bank clinical diagnostic criteria. [19] Patients having a weight range from (45-85) kg. Patients are aged more than 40 years old.

**UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria** [19]

**Step 1:** Establish the presence of bradykinesia (slowness of initiation of voluntary movement with reduced speed and amplitude of movements and/or the loss or decrease of automatic movements) plus at least one of the following: Rigidity, 4Y6 Hz resting tremor, Postural instability (not otherwise explained by primary visual, vestibular, cerebellar, or proprioceptive dysfunction)

**Step 2:** Evaluate for exclusionary criteria for the diagnosis of Parkinson disease. The absence of a history of: Repeated strokes with a stepwise progression of Parkinsonism, Repeated head injury, Definite encephalitis, Neuroleptic treatment at onset of symptoms, More than one affected relative (although this exclusion criterion is no longer commonly used), Any period of sustained remission, Oculogyric crises

Early severe autonomic involvement, Early severe dementia with disturbances of memory, language, and praxis

- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure
- OR a finding of:
- Strictly unilateral features after 3 years
- Negative response to large doses of levodopa (if malabsorption is excluded)
- Supranuclear gaze palsy
- Cerebellar signs
- Babinski sign
- Cerebral tumor or communicating hydrocephalus on neuroimaging

**Step 3:** Establish the presence of three or more of the supportive criteria for the diagnosis of Parkinson disease

- Unilateral onset
- Resting tremor present
- Progressive disorder
- Persistent asymmetry with symptoms worse on the side of onset
- Clear and definite response (70 to 100% improvement on Unified Parkinson's Disease Rating Scale) to levodopa
- Severe levodopa-induced chorea
- Levodopa response for 5 years or more
- Clinical course of 10 years or more

**The disease severity can assess by Stages of Hoehn and Yahr Scale** [20]

1.0 Unilateral involvement only
1.5 Unilateral and axial involvement
2.0 Bilateral involvement without impairment of balance
2.5 Mild bilateral disease with recovery on pull test
3.0 Mild to moderate bilateral disease; some postural instability; physically independent
4.0 Severe disability; still able to walk or stand unassisted
5.0 Wheelchair dependent or bedridden unless aided

**Exclusion criteria:**

1. Atypical parkinsonian syndromes (e.g. multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome).
3. Chronic renal failure.
4. Patients have other diseases like DM, cardiovascular and CNS diseases.
5. Patients take vitamins supplements.
6. Patients with abnormal parathyroid hormone.

All patients were screened according to a strict protocol consisting of a full neurological examination, standardized blood tests and electrolytes included serum Calcium and phosphate and parathyroid hormone, magnetic Resonance imaging of the brain and cardiac analysis including standard 12-lead electrocardiography in all patients and serum vitamin D3. Serum levels of 25(OH) D were stratified into normal (≥30 ng/ml), insufficient (≥20 to <30 ng/ml) and deficient (<20 ng/ml). [21]

**Statistical Analysis:**
Data were analyzed by means of statistical package for social sciences (SPSS) software programs. Values were expressed as mean ± SD. A comparison of continuous variables was performed by unpaired two-tailed Student's t test. A level of P<.05 (two-sided testing) was considered statistically significant.

**Result:** We was study 40 patients in-group I (PD patients), the Mean age of the patients was 59.225 ± 5.968 years and 40 healthy patient in-group II (control) with mean age 59.750 ± 5.674.

In the group I (PD patients), there was 24 Male and 16 female, with mean BMI 21.958 and residency distributed in to 23 urban and 17 rural. In the group II (control), there was 23 male and 17 female, with mean BMI 23.277 and residency distributed in to 28 urban and 12 rural (Table 2).

This study, show there is no significant difference between the two groups regarding the age, sex, BMI, or residency (Table 2).

We found that is a significant relationship between the two groups regarding the vitamin D level. In-group I (PD patients) the mean vitamin D level was 18.09 ± 8.56 and 24.89 ± 9.10 in-group II (p value 0.001). As shown in (table 3).

It is obvious that in Parkinson disease patients (group I), there was 15(37.5%) patients with normal VDL and 25(62.5%) had deficient VDL, while in healthy control (group II), there was 29(67.5%) normal VDL and 11 (27.5%) deficient VDL.

The frequency of serum (OH) vitamin D deficiency among Parkinson disease patients show: 8(20%) patients with mild deficiency (15-19 ng/dl), 10 (25%) patients with moderate deficiency (10-14 ng/dl) and 7 (17.5%) patients with severe deficiency (< 10 ng/dl).

There is no significant different in vitamin D level between male and female in Parkinson patients (group I) with p value 0.716 (table 4).
The state of Vitamin D .... Aqeel Kareem Hatem and Hayder Fadhil Lateef

**Frequency of Vitamin D Deficiency in Parkinson**

![Frequency of Vitamin D Deficiency in Parkinson](image)

**Table 4. Relation VDL Between Male and Female in PD**

<table>
<thead>
<tr>
<th>GROUP</th>
<th>N</th>
<th>Mean</th>
<th>Std. Deviation</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>VITD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>24</td>
<td>17.68</td>
<td>8.80</td>
<td>0.716</td>
</tr>
<tr>
<td>Female</td>
<td>16</td>
<td>18.70</td>
<td>8.42</td>
<td></td>
</tr>
</tbody>
</table>

**Discussion:** This is the first study to investigate vitamin D level in Iraqi patients with Parkinson disease compared to the age-matched healthy control. Vitamin D deficiency is an important condition in the elderly. The prevalence of neurodegenerative disease is also higher in these patients. The results of this study show that (62.5%) Parkinson patients enrolled in the study who had sufficient vitamin D level with mean ± SD was significantly lower (18.09 ± 8.56ng/ml) compared to (27.5%) of healthy controls without Parkinson disease with mean ± SD was significantly higher (24.89±9.10ng/ml) in healthy controls (P = < 0.001).

However, the finding of low levels of 25(OH)D in individuals with Parkinson could be explained by the insufficient synthesis in the skin as PD patients experience mobility problems more frequently than control healthy persons. This makes a PD patient less likely to get sun exposure and account for the higher prevalence of vitamin D deficiency. In addition, inadequate intake or absorption of vitamin D, low seafood intake, limited outdoor activities, and decreased awareness about fortification with vitamin D may affect vitamin D status in these groups. An alternative aspect was ruled out such as age, sex, and BMI, the impacts of these factors on vitamin D status were no significant. Several lines of evidence point to possible role of vitamin D in PD. Studies of brain tissue show that receptors for vitamin D are widely distributed in brain and are affected by PD suggested an important role in normal function. This result agree with study done in 2008 at Emory University School of Medicine establish both patients with Parkinson disease and Alzheimer disease had significantly lower vitamin D level. Also, approve in Study by Dr. Yoshino Sato, Department of Neurology, Kurume University Medical Center that found a high prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Furthermore this study is compatible with study done in Iran, at 2013 study include Eighty-three patients with Parkinson's disease (PD) were recruited using simple non-random sampling. 25-hydroxyvitamin D [25(OH)D3] was measured by Electro chemiluminesence scine immunomassey (ECLIA) The mean 25(OH) D3 concentration was lower in the PD population than in the normal group.

Accumulating data have provided evidence that 1α,25 dihydroxyvitamin D3 [1,25-(OH)2D3] is involved in brain function. Thus, the nuclear receptor for 1,25-(OH)2D3 has been localized in neurons and glial cells. The reported biological effects of 1,25-(OH)2D3 in the nervous system include the biosynthesis of neurotrophic factors and at least one enzyme involved in neurotransmitter synthesis. 1,25-(OH)2D3 can also inhibit the synthesis of inducible nitric oxide synthase and increase glutathione levels, suggesting a role for the hormone in brain detoxification pathways. Neuroprotective and immunomodulatory effects of this hormone have been described in several experimental models, indicating the potential value of 1,25-(OH)2D3 and pharmacological analogs in neurodegenerative and neuroimmune diseases. The vitamin D receptors found in high concentration in substantia nigra, the region of brain affected by PD, vitamin D exhibit a neuroprotective effect through antioxidant mechanisms, neuronal calcium regulation, immunomodulation leading to enhance nerve conduction and detoxification mechanism. According to gender in current study, there is no significant difference between male and female with Parkinson patients in VDL. This finding is compatible with study done in 2008 in Iran, at 2013 study include Eighty-three patients with Parkinson's disease (PD) were recruited using simple non-random sampling. 25-hydroxyvitamin D [25(OH)D3] was measured by Electro chemiluminescence scine immunomassey (ECLIA) The mean 25(OH) D3 concentration was lower in the PD population than in the normal group.

**References:**